Monthly Archives: November 2010

Clinical Trial Confirms Gleevec Reduces Recurrence

On April 12, the National Cancer Institute (NCI), the American College of Surgeons (ACOSOG) and Novartis pharmaceuticals announced that a phase III trial studying Gleevec use to prevent recurrence in patients whose primary Gastrointestinal Stromal Tumor (GIST) had been removed by surgery would be ended early because it had met its primary endpoint of increasing recurrence free survival with a statistically significant hazard ratio of 3.1.

By |2018-07-05T21:02:32-04:00November 27th, 2010|News|

Adjuvant Gleevec: To Take or Not to Take?

In presentations at the 2010 American Society of Clinical Oncologists conference (ASCO), Dr. Ronald DeMatteo, Memorial Sloan-Kettering Cancer Center (MSKCC) and Dr. Chris Corless, Oregon Health & Science University (OHSU), presented new data from the Z9001 adjuvant Gleevec trial. As Dr. DeMatteo noted, the presentations were geared towards answering two questions: Who should get adjuvant Gleevec and how long should they get it for? While the presentations went a long way towards answering who should get adjuvant Gleevec, there appears to be much that we do not know about how long they should get it for. Other ongoing trials may help shed more light on this question.

By |2018-07-05T18:46:37-04:00November 27th, 2010|GIST Education|
Go to Top